Annual CFF
$5.78 M
-$1.27 M-17.98%
31 December 2022
Summary:
Nymox Pharmaceutical annual cash flow from financing activities is currently $5.78 million, with the most recent change of -$1.27 million (-17.98%) on 31 December 2022. During the last 3 years, it has fallen by -$2.64 million (-31.39%).NYMX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$61.00 K
-$9000.00-17.31%
31 March 2023
Summary:
Nymox Pharmaceutical quarterly cash flow from financing activities is currently -$61.00 thousand, with the most recent change of -$9000.00 (-17.31%) on 31 March 2023.NYMX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$1.67 M
-$4.11 M-71.13%
31 March 2023
Summary:
Nymox Pharmaceutical TTM cash flow from financing activities is currently $1.67 million, with the most recent change of -$4.11 million (-71.13%) on 31 March 2023.NYMX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NYMX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -31.4% | -3.4% | -76.3% |
| 5 y5 years | -61.3% | +3.2% | -83.0% |
NYMX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -61.3% | -100.7% | -90.8% |
Nymox Pharmaceutical Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$61.00 K(+17.3%) | $1.67 M(-71.1%) |
| Dec 2022 | $5.78 M(-18.0%) | -$52.00 K(-13.3%) | $5.78 M(+0.1%) |
| Sept 2022 | - | -$60.00 K(-103.3%) | $5.77 M(-0.0%) |
| June 2022 | - | $1.84 M(-54.5%) | $5.77 M(-48.3%) |
| Mar 2022 | - | $4.05 M(-6962.7%) | $11.15 M(+58.3%) |
| Dec 2021 | $7.04 M(-16.4%) | -$59.00 K(0.0%) | $7.04 M(-0.0%) |
| Sept 2021 | - | -$59.00 K(-100.8%) | $7.05 M(-55.2%) |
| June 2021 | - | $7.22 M(<-9900.0%) | $15.72 M(+86.5%) |
| Mar 2021 | - | -$60.00 K(+3.4%) | $8.43 M(+0.1%) |
| Dec 2020 | $8.42 M(+78.3%) | -$58.00 K(-100.7%) | $8.42 M(+0.4%) |
| Sept 2020 | - | $8.62 M(<-9900.0%) | $8.39 M(-2983.5%) |
| June 2020 | - | -$71.00 K(+4.4%) | -$291.00 K(+2.1%) |
| Mar 2020 | - | -$68.00 K(-23.6%) | -$285.00 K(-106.0%) |
| Dec 2019 | $4.72 M(-68.4%) | -$89.00 K(+41.3%) | $4.72 M(-51.9%) |
| Sept 2019 | - | -$63.00 K(-3.1%) | $9.81 M(-17.4%) |
| June 2019 | - | -$65.00 K(-101.3%) | $11.88 M(-34.2%) |
| Mar 2019 | - | $4.94 M(-1.2%) | $18.04 M(+20.8%) |
| Dec 2018 | $14.93 M(+196.3%) | $5.00 M(+150.0%) | $14.93 M(+44.8%) |
| Sept 2018 | - | $2.00 M(-67.2%) | $10.31 M(-8.0%) |
| June 2018 | - | $6.10 M(+233.0%) | $11.21 M(+72.1%) |
| Mar 2018 | - | $1.83 M(+380.8%) | $6.52 M(+29.3%) |
| Dec 2017 | $5.04 M(-18.0%) | $381.00 K(-86.9%) | $5.04 M(-23.9%) |
| Sept 2017 | - | $2.90 M(+107.0%) | $6.62 M(+14.6%) |
| June 2017 | - | $1.40 M(+296.0%) | $5.78 M(+31.4%) |
| Mar 2017 | - | $354.00 K(-82.0%) | $4.40 M(-28.4%) |
| Dec 2016 | $6.15 M(+75.9%) | $1.97 M(-4.6%) | $6.15 M(+8.8%) |
| Sept 2016 | - | $2.06 M(>+9900.0%) | $5.65 M(+39.3%) |
| June 2016 | - | $20.30 K(-99.0%) | $4.06 M(-25.4%) |
| Mar 2016 | - | $2.10 M(+43.1%) | $5.44 M(+55.6%) |
| Dec 2015 | $3.50 M(-40.3%) | $1.47 M(+213.6%) | $3.50 M(-2.6%) |
| Sept 2015 | - | $468.00 K(-66.6%) | $3.59 M(-25.7%) |
| June 2015 | - | $1.40 M(+793.9%) | $4.83 M(+3.6%) |
| Mar 2015 | - | $156.90 K(-89.9%) | $4.67 M(-20.3%) |
| Dec 2014 | $5.86 M(-2.2%) | $1.56 M(-8.9%) | $5.86 M(+7.7%) |
| Sept 2014 | - | $1.71 M(+38.4%) | $5.44 M(-2.6%) |
| June 2014 | - | $1.24 M(-8.2%) | $5.58 M(+4.5%) |
| Mar 2014 | - | $1.35 M(+18.2%) | $5.34 M(-10.8%) |
| Dec 2013 | $5.99 M(+75.2%) | $1.14 M(-38.6%) | $5.99 M(-4.7%) |
| Sept 2013 | - | $1.86 M(+86.0%) | $6.29 M(+15.3%) |
| June 2013 | - | $997.50 K(-50.0%) | $5.45 M(+0.9%) |
| Mar 2013 | - | $2.00 M(+38.7%) | $5.40 M(+58.1%) |
| Dec 2012 | $3.42 M(+17.7%) | $1.44 M(+40.8%) | $3.42 M(-11.9%) |
| Sept 2012 | - | $1.02 M(+7.5%) | $3.88 M(+1.9%) |
| June 2012 | - | $950.00 K(>+9900.0%) | $3.81 M(+30.8%) |
| Mar 2012 | - | $9000.00(-99.5%) | $2.91 M(+0.3%) |
| Dec 2011 | $2.90 M(-37.6%) | $1.90 M(+100.0%) | $2.90 M(+48.6%) |
| Sept 2011 | - | $950.00 K(+1659.3%) | $1.95 M(-16.3%) |
| June 2011 | - | $54.00 K(-94.3%) | $2.33 M(-49.9%) |
| Dec 2010 | $4.66 M | $950.00 K(-28.6%) | $4.66 M(+7.7%) |
| Sept 2010 | - | $1.33 M(+55.6%) | $4.32 M(-1.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $855.00 K(-43.8%) | $4.40 M(-5.6%) |
| Mar 2010 | - | $1.52 M(+146.2%) | $4.66 M(+19.5%) |
| Dec 2009 | $3.90 M(+11.1%) | $617.50 K(-56.1%) | $3.90 M(-2.7%) |
| Sept 2009 | - | $1.41 M(+26.0%) | $4.01 M(+8.5%) |
| June 2009 | - | $1.12 M(+46.9%) | $3.70 M(+21.6%) |
| Mar 2009 | - | $760.00 K(+4.6%) | $3.04 M(-13.4%) |
| Dec 2008 | $3.51 M(-28.6%) | $726.80 K(-33.5%) | $3.51 M(-3.4%) |
| Sept 2008 | - | $1.09 M(+137.1%) | $3.63 M(+28.1%) |
| June 2008 | - | $460.70 K(-62.6%) | $2.84 M(-37.6%) |
| Mar 2008 | - | $1.23 M(+44.5%) | $4.55 M(-7.5%) |
| Dec 2007 | $4.91 M(+5.2%) | $851.20 K(+188.3%) | $4.91 M(-7.1%) |
| Sept 2007 | - | $295.20 K(-86.4%) | $5.29 M(-6.5%) |
| June 2007 | - | $2.17 M(+35.7%) | $5.66 M(+26.4%) |
| Mar 2007 | - | $1.60 M(+30.5%) | $4.48 M(-4.2%) |
| Dec 2006 | $4.67 M(+72.0%) | $1.22 M(+84.9%) | $4.67 M(+16.8%) |
| Sept 2006 | - | $662.50 K(-33.1%) | $4.00 M(-4.5%) |
| June 2006 | - | $989.80 K(-44.8%) | $4.19 M(+1.9%) |
| Mar 2006 | - | $1.79 M(+224.2%) | $4.11 M(+51.4%) |
| Dec 2005 | $2.72 M(-23.8%) | $553.30 K(-35.1%) | $2.72 M(-11.2%) |
| Sept 2005 | - | $853.10 K(-6.5%) | $3.06 M(-3.5%) |
| June 2005 | - | $912.20 K(+129.4%) | $3.17 M(+12.2%) |
| Mar 2005 | - | $397.60 K(-55.7%) | $2.83 M(-20.7%) |
| Dec 2004 | $3.56 M(-7.0%) | $897.60 K(-6.9%) | $3.56 M(-0.7%) |
| Sept 2004 | - | $963.70 K(+70.1%) | $3.59 M(-6.8%) |
| June 2004 | - | $566.50 K(-50.1%) | $3.85 M(+2.4%) |
| Mar 2004 | - | $1.14 M(+23.0%) | $3.76 M(-1.9%) |
| Dec 2003 | $3.83 M(+28.7%) | $922.80 K(-24.7%) | $3.83 M(+1.3%) |
| Sept 2003 | - | $1.23 M(+158.0%) | $3.78 M(+15.4%) |
| June 2003 | - | $474.90 K(-60.7%) | $3.28 M(+6.3%) |
| Mar 2003 | - | $1.21 M(+38.5%) | $3.08 M(+3.5%) |
| Dec 2002 | $2.98 M(+4.1%) | $871.80 K(+20.8%) | $2.98 M(+6.9%) |
| Sept 2002 | - | $721.40 K(+157.0%) | $2.78 M(-8.5%) |
| June 2002 | - | $280.70 K(-74.5%) | $3.04 M(-6.8%) |
| Mar 2002 | - | $1.10 M(+62.4%) | $3.27 M(+14.2%) |
| Dec 2001 | $2.86 M(-33.3%) | $679.20 K(-30.8%) | $2.86 M(+6.9%) |
| Sept 2001 | - | $981.60 K(+95.6%) | $2.67 M(+22.6%) |
| June 2001 | - | $501.80 K(-28.0%) | $2.18 M(+30.4%) |
| Mar 2001 | - | $696.50 K(+40.8%) | $1.67 M(-60.9%) |
| Dec 2000 | $4.28 M(+294.7%) | $494.80 K(+1.2%) | $4.28 M(+10.5%) |
| Sept 2000 | - | $488.80 K(-7082.9%) | $3.88 M(-0.3%) |
| June 2000 | - | -$7000.00(-100.2%) | $3.89 M(-5.0%) |
| Mar 2000 | - | $3.31 M(+3741.5%) | $4.09 M(+277.1%) |
| Dec 1999 | $1.09 M(-81.7%) | $86.10 K(-82.8%) | $1.09 M(-49.0%) |
| Sept 1999 | - | $501.70 K(+154.2%) | $2.13 M(+48.3%) |
| June 1999 | - | $197.40 K(-34.2%) | $1.43 M(-61.7%) |
| Mar 1999 | - | $300.10 K(-73.4%) | $3.74 M(-37.0%) |
| Dec 1998 | $5.94 M(+74.8%) | $1.13 M(-689.6%) | $5.94 M(+23.4%) |
| Sept 1998 | - | -$191.20 K(-107.6%) | $4.81 M(-3.8%) |
| June 1998 | - | $2.50 M(+0.3%) | $5.00 M(+100.3%) |
| Mar 1998 | - | $2.50 M | $2.50 M |
| Dec 1997 | $3.40 M | - | - |
FAQ
- What is Nymox Pharmaceutical annual cash flow from financing activities?
- What is the all time high annual CFF for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical TTM cash flow from financing activities?
- What is the all time high TTM CFF for Nymox Pharmaceutical?
What is Nymox Pharmaceutical annual cash flow from financing activities?
The current annual CFF of NYMX is $5.78 M
What is the all time high annual CFF for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high annual cash flow from financing activities is $14.93 M
What is Nymox Pharmaceutical quarterly cash flow from financing activities?
The current quarterly CFF of NYMX is -$61.00 K
What is the all time high quarterly CFF for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high quarterly cash flow from financing activities is $8.62 M
What is Nymox Pharmaceutical TTM cash flow from financing activities?
The current TTM CFF of NYMX is $1.67 M
What is the all time high TTM CFF for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high TTM cash flow from financing activities is $18.04 M